RE-BVS – Piemonte Repository

Sfoglia per AUTORE
KIM SW
Collezione AOU San Luigi di Orbassano

Items : 4

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11.

2023
AOU San Luigi di Orbassano

Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA;

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. in Lancet (London, England) / Lancet. 2023 Mar 4;401(10378):733-746. doi: 10.1016/S0140-6736(23)00221-0. Epub 2023 Feb 7.

2023
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10.

2022
AOU San Luigi di Orbassano

Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES;

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. in Investigational new drugs / Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1. Epub 2016 Jun 27.

2016
AOU San Luigi di Orbassano

Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M;